Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

eIF4E inhibitor

National Institute for Health and Care Excellence NICE logo

Good NICE news for Pfizer, but Dendreon drug rejected

Kidney cancer drug Inlyta backed but prostate cancer treatment Provenge is not

- PMLiVE

Early win for Pfizer as Remicade biosimilar launches in West Europe

Hospira launchescopycat version of Janssen/MSD’s drug in major European markets

- PMLiVE

Pfizer UK appoints Erik Nordkamp as new managing director

He takes over from Jonathan Emms who moves to a global role within the firm

- PMLiVE

Pfizer’s bid for Hospira could lead to break-up

Questions posed whether $15bn bid will be profitable for the firm

- PMLiVE

Pfizer’s Ibrance wins early breast cancer approval in US

FDA’s decision come two months ahead of schedule

- PMLiVE

Products over pipeline in Pfizer’s acquisition targets, hints CEO

Sale forecasts for 2015 are down by up to $5bn compared to last year

- PMLiVE

Pfizer’s Prevenar 13 price cut slammed by MSF

Global health charity says reduction of 20 cents is "negligible"

Pfizer strikes genetic research deal with 23andMe

Lupus study and research community forms just one part of their collaboration

- PMLiVE

Pfizer names head of Germany business

Peter Albiez has been with pharma company since 1996

- PMLiVE

Call for GSK and Pfizer to reduce vaccine price

MSF campaigns to lower cost of pneumococcal shot to $5 per child in developing countries

- PMLiVE

Pfizer buys majority stake in Redvax

Will see the US pharma company gain access to early stage vaccine projects

Bone Therapeutics looks to Pfizer for clinical head

Guy Heynen has 35 years of industry experience

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links